REVO Oncology Diagnostics Inc. — SEC Form D Filing
REVO Oncology Diagnostics Inc. filed an SEC Form D on April 13, 2026, reporting $270K raised in Health Care.
Form D filing details
- Filing
- SEC Form D
- Filing date
- April 13, 2026
- Amount reported
- $270K
- Round stage
- Seed
- Industry
- Health Care
- Website
- https://revohealth.com/
What the company does
Securities: Simple Agreement for Future Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Physician practices often face challenges in managing fragmented data and optimizing care pathways, which can negatively impact patient outcomes and operational efficiency.
Solution
Revo provides data intelligence and management services that help physician practices streamline operations, improve patient care, and make informed business decisions.
Verdict
Investors said yes at that moment because they recognized a pressing need for data management in physician practices amid increasing operational demands, not because the solution demonstrated clear novelty or distinct effects on outcomes. They were implicitly betting on the potential for a high adoption rate among physician leaders who are seeking efficiency gains, while the limited upside lies in competing against established players that may offer more comprehensive solutions, diminishing the durability of Revo's value proposition.
Source: SEC EDGAR Form D filing